Guardant Health, Inc. raised financial guidance for the full year of 2024. For the period, the company expects revenue excluding screening to be in the range of $675 to $685 million, representing growth of 20% to 21% compared to full year 2023 This compares to the prior range of $655 to $670 million, representing growth of 16% to 19%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
31.19 USD | +11.43% | +19.55% | +15.30% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.30% | 3.82B | |
+2.34% | 2.33B | |
-19.52% | 2.02B | |
-20.72% | 1.67B | |
+31.45% | 1.14B | |
+21.58% | 760M | |
-9.39% | 697M | |
-21.63% | 566M | |
-1.29% | 290M | |
-15.53% | 163M |
- Stock Market
- Equities
- GH Stock
- News Guardant Health, Inc.
- Guardant Health, Inc. Raises Financial Guidance for the Full Year of 2024